The Handoff: Your Week in Rheumatology News – 4/7/17
WCO 2017, FDA grants Rituxan Breakthrough Therapy status, and a close-up of pediatric Sjögren’s syndrome highlight this week’s The Handoff.
WCO 2017, FDA grants Rituxan Breakthrough Therapy status, and a close-up of pediatric Sjögren’s syndrome highlight this week’s The Handoff.
The trabecular bone score may provides an acute, albeit indirect, measurement of bone quality in patients with type 2 diabetes.
Study examines the predictive value for vertebral fractures of bone mineral density and bone turnover markers after a 5-year drug holiday.
A retrospective study examined the risk of developing fractures in postmenopausal women with osteoporosis who discontinued bisphosphonate therapy.
An international team of researchers collected data from the Osteoarthritis Initiative to determine the effect of knee osteoarthritis on development of hypertension.
A small study from Romania evaluated whether the presence of osteoarthritis had an effect on the parameters used to evaluate disease activity in patients with early rheumatoid arthritis.